The first clinical program testing sublingual esketamine film for PTSD — and exploring the same molecule as a novel adjunctive treatment for autoimmune disease. One film, two indications. The mechanism that rewires trauma also modulates the immune pathways targeted by Skyrizi, Cosentyx, and Humira.
*Sertraline (1999) and paroxetine (2001) are the only FDA-approved PTSD medications. Both are 1990s SSRIs. No novel mechanism has been approved in over 25 years. Sources: FDA, SAMHSA, Grand View Research.
Emerging evidence shows that PTSD is associated with chronically elevated levels of pro-inflammatory cytokines — including IL-6, TNF-α, and CRP — that persist long after the traumatic event. These biomarkers disrupt hippocampal neurogenesis, impair BDNF signaling, and perpetuate the hyperarousal and avoidance symptoms that define the disorder.
Existing pharmacotherapies — SSRIs, SNRIs, prazosin — address neurotransmitter balance but leave the inflammatory substrate largely untreated. This is a core reason why 40–60% of PTSD patients fail to achieve remission.
3.6 million treatment-resistant PTSD patients have already exhausted every approved option. Only 2 FDA-approved drugs exist for the primary indication — both over 20 years old — and neither addresses the neurobiological substrate. Meanwhile, these same inflammatory markers (IL-6, TNF-α, IL-17, interferon α/β) are the precise targets of the world’s highest-revenue autoimmune biologics — Skyrizi ($20B+/year class), Cosentyx, Humira, and Actemra. One inflammatory substrate. Two diseases. One therapeutic opportunity.
Passos et al. (2015). "Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression." JAMA Psychiatry, 72(2), 192–200. Meta-analysis of 20 studies, N>1,000.
Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression — not PTSD. While its mechanism is highly relevant, its in-clinic model and $6,000–8,000/month price tag create a prohibitive access barrier. Meanwhile, unregulated compounded troches ($100–150/month, no oversight, dissociative doses) fill the vacuum with no FDA path, no insurance pathway, and no standardized safety monitoring.
The gap between Spravato and unregulated troches is where Project Lucid lives: FDA-regulated, low-dose, at-home, and designed from the ground up for PTSD.
And these same PTSD patients carry 2× the rate of autoimmune disease (O’Donovan et al., 2015; N=666,269; confirmed by Cassidy et al. 2025 meta-analysis, N=1.98M, RR=1.291). The mechanism that rewires trauma also modulates the immune pathways targeted by Skyrizi, Cosentyx, and Humira — opening a second indication on the immunology shelf.
The competitive landscape shifted materially in August 2024, when the FDA rejected MDMA-assisted therapy for PTSD — the most high-profile novel approach in years — citing data integrity concerns and functional unblinding limitations inherent to psychedelic trials. The rejection underscores investor demand for candidates with cleaner, placebo-controlled evidence packages. Ketamine’s RCT record in PTSD is precisely that.
The 50mg sublingual esketamine film (manufactured by LTS Lohmann) operates through two complementary mechanisms simultaneously — rapid neuroplasticity induction and direct anti-inflammatory action. Project Lucid’s clinical program is the first to test this film for PTSD and explore its potential as an autoimmune adjunctive. No existing treatment targets both.
Durability comes from frequency — not dose. And the same mechanism that rewires trauma modulates IL-17, TNF-α, and interferon signaling — the targets of Skyrizi, Humira, and Cosentyx.
NMDA receptor antagonism triggers downstream BDNF release, promoting synaptogenesis in the prefrontal cortex and hippocampus within hours — not weeks.
Esketamine directly suppresses pro-inflammatory cytokines IL-6 and TNF-α — addressing the neuroinflammatory substrate that conventional PTSD treatments leave untreated.
Sublingual film achieves ~29% bioavailability with rapid Tmax (~19 min) — parent-drug Cmax comparable to Spravato 56–84mg intranasal — without requiring in-clinic administration after the first supervised dose.
| Dimension | Project Lucid | Spravato (J&J) | IV Ketamine Clinics |
|---|---|---|---|
| Delivery | Sublingual film | Nasal spray | Intravenous infusion |
| Active Ingredient | Esketamine (50mg) | Esketamine (56–84mg) | Racemic ketamine |
| Setting | At-home after first clinic dose | In-clinic only (2-hr monitoring) | In-clinic only (45–60 min infusion) |
| Dosing Frequency | 3×/week | 2×/week → 1×/week maintenance | Varies (1–2×/week) |
| PTSD Indication | Primary target | Not indicated (TRD only) | Off-label |
| Neuroimmune Mechanism | Core thesis: dual-pathway | Not positioned | Not positioned |
| Dose Level | Sub-dissociative | Can be dissociative | Often dissociative |
| Cost Model | Designed for accessibility | ~$900/session (before insurance) | $400–800/infusion |
| Reimbursement Target | Insurance-reimbursable target | Limited (specialty pharmacy) | Rarely covered |
The sublingual film is the therapeutic. The digital monitoring platform is what makes at-home administration safe, measurable, and scalable. This is the technology our patent protects.
All 12 doses administered under direct clinical supervision with 2-hour post-dose monitoring. Vitals, CADSS, and SpO₂ collected at every session. Establishes the baseline safety profile.
First doses in clinic, maintenance doses transition to at-home with real-time digital monitoring. The platform tracks vitals, mood, dissociation, and safety checkpoints — flagging alerts to the treating clinician before, during, and after each dose.
FDA-regulated at-home esketamine with continuous digital safety infrastructure. Remote vitals, real-time dissociation scoring, between-dose symptom tracking, telehealth check-ins, and automated safety escalation. Dual reimbursement pathway: positioned at ~$64K/year as a psychiatric therapy, or ~$250K/year as an adjunctive immunologic on the rheumatology shelf.
Patent-pending: Digital Systems for Remote Administration and Monitoring of Sublingual Esketamine for PTSD (Provisional Serial Nos. 63/785,736; 63/799,047; 63/804,512). PCT international application filed April 2026.
Project Lucid is an IRB-ready Phase 1/2 open-label pilot — N=12 (up to 15 enrolled to ensure 12 completers) — studying 50mg sublingual esketamine 3×/week for 4 weeks in adults with co-occurring PTSD and autoimmune disease. CAPS-5 is the primary endpoint; autoimmune disease activity is exploratory. One pilot, two indication readouts. Each milestone below represents an investor catalyst event.
Protocol LUCID-PTSD-2026-001 is IRB-ready. Study design, inclusion/exclusion criteria, safety monitoring plan, and informed consent documents are complete. IRB submission and approval targeted Q3 2026.
ActiveEnrollment of N=12 adults with confirmed PTSD (CAPS-5 ≥ 26) and co-occurring autoimmune disease. Baseline biomarker panel (IL-6, TNF-α, CRP, BDNF) and autoimmune disease activity scores collected alongside CAPS-5 and PCL-5.
First reportable data: adverse event profile, tolerability at 50mg SL dose, early biomarker trends. DSMB review of safety data. Interim PCL-5 and CAPS-5 signals presented.
Full primary outcome data: CAPS-5 change from baseline (primary), PCL-5 (secondary), inflammatory biomarker panel change, PSQI sleep quality. Results prepared for scientific conference presentation.
Investigational New Drug application filing and FDA pre-submission meeting request. Successful pilot data supports Phase 2 design and partnership/out-licensing discussions.
All dosing sessions include 2-hour post-dose digital monitoring with validated dissociation assessment (CADSS at 40 minutes) and vital sign tracking. Explicit discharge criteria gate home release. C-SSRS suicidality screening at every visit. DSMB review after the first 6 patients. Stopping rules for any serious adverse event. The safety protocol was designed to demonstrate clinical viability — not just regulatory compliance.
The case for Project Lucid is not speculative — it rests on a converging body of clinical, pharmacokinetic, and mechanistic evidence. Repeated IV ketamine 3×/week produces PTSD response rates of 67–77% with Cohen's d up to 1.9. The 50 mg SL OTF achieves parent-drug Cmax comparable to Spravato 56–84 mg. And at-home sublingual ketamine has a robust real-world safety record across 11,441 patients.
Protocol: 6 IV infusions (0.5 mg/kg), 3×/week × 2 weeks. Directly establishes the 3×/week schedule as evidence-based for PTSD.
View on PubMedAmong the largest effect sizes ever reported in psychiatric pharmacotherapy. Project Lucid's digital platform is designed to deliver this combination model at home.
View on PubMed CentralThe 50 mg SL OTF — the same LTS Lohmann platform underlying Project Lucid — was characterized in a Phase 1 PK trial by Dahan et al. (2022). The key finding: the OTF achieves parent-drug S-ketamine Cmax of ~96 ng/mL, comparable to Spravato 56–84 mg intranasal — not half a Spravato 28 mg, as the lower systemic AUC might suggest.
| Parameter | 50 mg SL OTF Project Lucid |
Spravato 28 mg IN | Spravato 56 mg IN | Spravato 84 mg IN |
|---|---|---|---|---|
| Bioavailability | ~29% | ~48% | ~48% | ~48% |
| Systemic S-ket delivered | ~14.5 mg | ~13.4 mg | ~26.9 mg | ~40.3 mg |
| S-ketamine Cmax (ng/mL) | ~96 | 43.8 | 72.5 | 101.0 |
| S-norketamine Cmax (ng/mL) | ~276 | 59.1 | 119.7 | 180.0 |
| Norketamine : Ketamine ratio | ~4.6× | ~1.4× | ~1.7× | ~1.8× |
| Tmax (min) | ~19 | 20–40 | 20–40 | 20–40 |
Source: Dahan et al. 2022 (OTF); J&J / FDA Clinical Pharmacology Review (Spravato). IN = intranasal. Spravato bioavailability includes nasal + GI components.
The SL route’s heavy hepatic first-pass metabolism generates a pharmacologically advantageous metabolite profile. S-norketamine Cmax (276 ng/mL) is 4.6× the parent drug — vs. 1.4–1.8× for Spravato intranasal. The OTF also generates meaningful S-hydroxynorketamine (S-HNK, Cmax ~101 ng/mL), essentially absent in intranasal delivery. Both metabolites carry independent antidepressant and synaptogenic activity without dissociative or abuse-related properties. The SL route is not a compromise — it is a feature.
This metabolite advantage now has transcriptomic confirmation: Wellington et al. (2025, OKTOP cohort) demonstrated that oral ketamine induces a two-phase immune response in PTSD patients — acute IL-6/IL-1β suppression followed by sustained immune reconstitution with an 8.8-fold increase in pathway activity. The modulated pathways (IL-17 z=3.36, interferon α/β z=4.0, cytokine storm z=4.26) are the same targets as Skyrizi (IL-23/IL-17), Cosentyx (IL-17A), Humira (TNFα), and Actemra (IL-6). This is the mechanistic bridge between Project Lucid’s PTSD indication and the autoimmune adjunctive opportunity.
An honest appraisal of what is known, what is inferred, and what gap Project Lucid fills.
| Scientific Dimension | Evidence Level | Key Sources |
|---|---|---|
| PTSD unmet need | Strong | VA/DoD CPG 2023; PTSD market data |
| Ketamine efficacy in PTSD (3×/week IV) | Strong (RCT) | Feder 2021, Feder 2025 |
| 50 mg OTF pharmacokinetics | Strong (Phase 1) | Dahan et al. 2022 |
| Therapeutic dose adequacy of 50 mg OTF | Moderate-Strong | Cmax ~96 ng/mL comparable to Spravato 56–84 mg |
| S-HNK / S-norketamine metabolite activity | Moderate–Strong | Zanos 2016; Bottemanne 2025; Wellington 2025 (OKTOP transcriptomics: 8.8× pathway activation via oral route) |
| 3×/week schedule neuroplasticity rationale | Strong | ASL imaging; Singh et al.; Feder protocols |
| Fear reconsolidation mechanism | Moderate (Phase 2) | Morrison et al. 2023 |
| At-home SL ketamine safety (N=11,441) | Strong (prospective) | Wolfson et al. 2023; Mindbloom PTSD data |
| Long-term esketamine safety (129 sessions) | Moderate (N=20) | Bozan et al. 2026; SUSTAIN-3 |
| SL esketamine efficacy specifically in PTSD | Absent — gap we fill | N/A — rationale by extrapolation. This is what LUCID-PTSD-2026-001 directly addresses. |
Pivotal RCT establishing 3×/week ketamine as evidence-based for PTSD. 67% vs. 20% response rate; d=1.13; CAPS-5 reduction of 11.9 points vs. 2.4 for midazolam.
View on PubMedOpen-label trial combining 3×/week IV ketamine with WET. d=1.9 — among the largest effect sizes in psychiatric pharmacotherapy. 69% response at Week 12; 61.5% no longer meeting DSM-5 criteria at 6 months.
View on PMCPhase 1 PK trial of the LTS 50 mg S-ketamine OTF. Establishes ~29% bioavailability, Cmax ~96 ng/mL (comparable to Spravato 56–84 mg), and the 4.6× norketamine metabolite advantage.
View on PMCRandomized crossover study (N=27) showing ketamine after trauma memory reactivation significantly reduced amygdala reactivity to trauma cues at 30-day follow-up. Direct evidence that ketamine can rewrite traumatic memories during the reconsolidation window.
View on NatureLargest prospective safety dataset for sublingual ketamine. At average doses 7× the Project Lucid dose: adverse events 3–5%, serious adverse events 0.05%, intense dissociation requiring discontinuation 0.1%. No drug-related fatalities.
View on PMCMost comprehensive long-term esketamine safety data to date: 20 TRD patients, mean 129 intranasal sessions over 2.5 years. No serious adverse events. Side effects mild and transient at all sessions. 85% of patients improved after 129 sessions.
View on PMCMeta-analysis of 20 studies (N>1,000) demonstrating significantly elevated IL-6, IL-1β, and CRP in PTSD. Establishes the neuroinflammatory substrate that esketamine directly targets through cytokine suppression.
View on PubMedComprehensive review of NMDA receptor antagonism, downstream BDNF upregulation, and AMPA potentiation. Establishes that the therapeutic mechanism extends well beyond glutamate modulation and supports the rationale for repeated sub-dissociative dosing.
View on PubMedReal-world dataset of 1,247 patients receiving at-home sublingual ketamine. Significant improvement at 1, 2, and 3 months. Directly validates Project Lucid’s delivery route and monitoring model at scale.
View on PubMed6-week low-dose oral ketamine trial in 25 PTSD patients. Confirmed BDNF and VEGF-A changes — the first comprehensive biomarker evidence that oral ketamine drives neuroplasticity-mediated PTSD symptom reduction. Direct biological analog to Project Lucid’s sublingual delivery model.
Double-blind, active-controlled crossover RCT in 33 treatment-resistant PTSD patients. IM ketamine vs. fentanyl (psychoactive control). Ketamine at 1 mg/kg produced substantial, sustained PTSD severity reduction (IESR). Confirms efficacy even against an active psychoactive comparator — ruling out placebo or expectancy effects.
RNA transcriptomics in N=23 PTSD patients receiving 6-week oral ketamine. Identified 1,154 differentially expressed genes with an 8.8-fold enhancement in pathway activity from short-term to sustained timepoints. Demonstrated a two-phase immune response: acute pro-inflammatory cytokine suppression (IL-6, IL-1β, CXCL8) followed by sustained immune reconstitution and tissue repair. Key pathways: interferon α/β signalling, IL-17, cytokine storm modulation. The most granular molecular proof to date that oral ketamine directly addresses the neuroinflammatory substrate in PTSD — and the strongest validation of Project Lucid’s Aim 3 biomarker strategy.
View on PubMedDallas-based psychiatrist and PTSD specialist who developed Project Lucid directly from clinical ketamine experience. Sponsor-Investigator of LUCID-PTSD-2026-001 — an IRB-ready Phase 1/2 open-label pilot of 50mg sublingual esketamine for PTSD with co-occurring autoimmune disease.
The clinical premise of Project Lucid sits at the intersection of three bodies of evidence that have not previously been connected: Feder et al.’s RCT-validated 3×/week IV ketamine protocol, Dahan et al.’s Phase 1 PK characterization of the 50mg SL OTF, and Wolfson et al.’s at-home safety dataset of N=11,441. The synthesis is Dr. Idell’s.
Protocol LUCID-PTSD-2026-001 is patent-pending (administration protocol and digital monitoring system), IRB-ready, and targeting Q4 2026 enrollment. Dr. Idell is the Sponsor-Investigator.
Dr. Mukesh Kumar, PhD, RAC
CEO & Founder, FDAMap — Washington, DC. 20+ years in FDA regulatory affairs. 150+ clinical trials across 34 countries. Confirmed 505(b)(2) pathway viability for Project Lucid.
Dr. Steven Idell, MD, PhD
Pulmonary & Critical Care Physician. Temple Chair in Pulmonary Fibrosis. 40 years of continuous NIH funding. Founder of Lung Therapeutics (acquired → Rein Therapeutics). Deep translational drug development expertise.
EMMES Corporation
Full-service CRO engaged for Phase 1/2 pilot study design. Specializes in Phase I–IV trials, biostatistics, pharmacovigilance, and FDA regulatory affairs. AI-enabled trial management.
Neurolivd
Rachel Wurzman, PhD (CEO) — neuroscientist, neuroethicist, and licensed clinical social worker. Jon Nelson (Chief Lived Experience Officer) — healthcare executive and mental health advocate. Neurolivd embeds lived experience into every stage of product development — from protocol design through commercialization. Project Lucid integrates the patient voice from day one, not as an afterthought.
A $3.5B PTSD market and a $120B+ autoimmune market — both addressable with one platform. No biologic holds a PTSD primary indication. No novel mechanism has been approved in 25 years. And the same patients carry 2× the autoimmune disease burden. The window for a dual-indication ketamine candidate has not been wider.
PTSD patients have a 2× higher rate of autoimmune disease (O’Donovan et al., 2015; N=666,269). Wellington et al. (2025) demonstrated that oral ketamine modulates the identical inflammatory pathways targeted by leading autoimmune biologics — IL-17 signaling, interferon α/β, and cytokine storm pathways. Project Lucid’s Phase 1/2 enrolls patients with co-occurring PTSD and autoimmune disease, generating preliminary data for both indications from a single trial.
Primary CAPS-5 endpoint. 505(b)(2) IND pathway confirmed. Phase 2 RCT → NDA. Positioned alongside Spravato at ~$64K/year reimbursement.
Exploratory autoimmune disease activity endpoints in Phase 1/2. If signal → Phase 2b as adjunctive to standard-of-care immunologics (Skyrizi, Cosentyx, Humira). Positioned on the immunology shelf at ~$250K/year reimbursement.
Whichever indication shows the stronger signal becomes the lead program. The other becomes the follow-on. Either way, the Phase 1/2 data is the catalyst — one pilot, two shots on goal.
Whether you're evaluating an investment or exploring a clinical collaboration, we welcome direct conversations.
Seed-stage funding opportunity. Supporting Phase 1/2 pilot completion, biomarker data collection, and IND preparation. Reach out to receive the full investor deck, protocol summary, and financial projections.
Academic medical center partnerships, site collaboration, and key opinion leader engagement. Trauma psychiatrists, psychopharmacologists, and drug delivery researchers are welcome to reach out about the science and study design.
